vTv Therapeutics (NASDAQ:VTVT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners began coverage on vTv Therapeutics in a research note on Monday, December 9th. They set a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Stock Performance

vTv Therapeutics stock opened at $17.35 on Thursday. The stock has a market cap of $55.35 million, a PE ratio of -3.83 and a beta of 1.07. The stock has a 50-day moving average of $17.32 and a two-hundred day moving average of $15.52. vTv Therapeutics has a one year low of $12.12 and a one year high of $29.19.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.32. The company had revenue of $0.02 million during the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VTVT. JPMorgan Chase & Co. acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at about $25,000. Geode Capital Management LLC raised its position in vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares in the last quarter. Finally, FMR LLC acquired a new position in vTv Therapeutics in the third quarter valued at approximately $2,402,000. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.